{"id":46228,"date":"2022-07-15T14:01:54","date_gmt":"2022-07-15T12:01:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/"},"modified":"2022-07-15T14:01:54","modified_gmt":"2022-07-15T12:01:54","slug":"aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/","title":{"rendered":"Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022"},"content":{"rendered":"<div>\n<p>EVANSTON, Ill.&#8211;(BUSINESS WIRE)&#8211;Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220715005076\/en\/838578\/5\/AptinyxLogo_FullColor_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220715005076\/en\/838578\/21\/AptinyxLogo_FullColor_RGB.jpg\"><\/a><\/p>\n<p>\nTo access the live conference call, please dial (888) 660-6390 (domestic) or (929) 203-1902 (international) and refer to conference ID 4855909. A live audio webcast of the event will be available on the Investors &amp; Media section of Aptinyx\u2019s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.aptinyx.com%2Fevents-presentations&amp;esheet=52781743&amp;newsitemid=20220715005076&amp;lan=en-US&amp;anchor=https%3A%2F%2Fir.aptinyx.com&amp;index=1&amp;md5=197f0316803b54ab963a7520e9e0ca06\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/ir.aptinyx.com<\/a>. A replay of the webcast will be archived on Aptinyx\u2019s website for 30 days following the event.\n<\/p>\n<p>\n<b>About Aptinyx<\/b>\n<\/p>\n<p>\nAptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate\u2014rather than block or over-activate\u2014NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including fibromyalgia, cognitive impairment, and post-traumatic stress disorder. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aptinyx.com&amp;esheet=52781743&amp;newsitemid=20220715005076&amp;lan=en-US&amp;anchor=www.aptinyx.com&amp;index=2&amp;md5=3dd1ea53387200f3eaadc65cb52141c4\" rel=\"nofollow noopener\" shape=\"rect\">www.aptinyx.com<\/a>.\n<\/p>\n<p>\nSource: Aptinyx Inc.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor &amp; Media Contact:<\/b><br \/>Patrick Flavin<br \/>\n<br \/>Aptinyx Inc.<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#x6f;:&#x69;&#114;&#x40;&#x61;p&#x74;&#105;&#x6e;&#x79;x&#x2e;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#105;&#x72;&#64;&#x61;&#112;&#x74;&#105;&#x6e;&#121;&#x78;&#46;&#x63;o&#x6d;<\/a> or <a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x63;&#x6f;&#x72;&#x70;&#x6f;&#x72;&#x61;&#x74;&#x65;&#x40;&#x61;&#x70;&#x74;&#x69;&#x6e;&#x79;&#x78;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">c&#111;&#114;&#112;&#x6f;&#x72;&#x61;te&#64;&#97;&#x70;&#x74;&#x69;&#x6e;yx&#46;&#99;&#x6f;&#x6d;<\/a><br \/>847-871-0377\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>EVANSTON, Ill.&#8211;(BUSINESS WIRE)&#8211;Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46228","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"EVANSTON, Ill.&#8211;(BUSINESS WIRE)&#8211;Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-15T12:01:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220715005076\/en\/838578\/21\/AptinyxLogo_FullColor_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022\",\"datePublished\":\"2022-07-15T12:01:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\\\/\"},\"wordCount\":275,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005076\\\/en\\\/838578\\\/21\\\/AptinyxLogo_FullColor_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\\\/\",\"name\":\"Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005076\\\/en\\\/838578\\\/21\\\/AptinyxLogo_FullColor_RGB.jpg\",\"datePublished\":\"2022-07-15T12:01:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005076\\\/en\\\/838578\\\/21\\\/AptinyxLogo_FullColor_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005076\\\/en\\\/838578\\\/21\\\/AptinyxLogo_FullColor_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/","og_locale":"en_US","og_type":"article","og_title":"Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022 - Pharma Trend","og_description":"EVANSTON, Ill.&#8211;(BUSINESS WIRE)&#8211;Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-15T12:01:54+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220715005076\/en\/838578\/21\/AptinyxLogo_FullColor_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022","datePublished":"2022-07-15T12:01:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/"},"wordCount":275,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220715005076\/en\/838578\/21\/AptinyxLogo_FullColor_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/","url":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/","name":"Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220715005076\/en\/838578\/21\/AptinyxLogo_FullColor_RGB.jpg","datePublished":"2022-07-15T12:01:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220715005076\/en\/838578\/21\/AptinyxLogo_FullColor_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220715005076\/en\/838578\/21\/AptinyxLogo_FullColor_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/aptinyx-to-report-second-quarter-2022-financial-results-on-thursday-august-4-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46228"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46228\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}